Quick Answer
RedHill Biopharma Ltd. reported Research And Development Expense of $1.59 million for the year ending 2024.
- RedHill Biopharma Ltd. showed a decrease of -55.0% in Research And Development Expense from 2023 to 2024.
- This data is from RedHill Biopharma Ltd.'s annual report (Form 10-K), filed with the SEC on April 10, 2025.
- XBRL data for this metric is available from 2015 to 2024 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2015 to 2024), RedHill Biopharma Ltd.'s Research And Development Expense has declined by 91.1%.
- Historical annual values: Fiscal year 2024: $1.59 million | Fiscal year 2023: $3.53 million | Fiscal year 2022: $7.28 million | Fiscal year 2021: $29.50 million | Fiscal year 2020: $16.49 million | Fiscal year 2019: $17.42 million | Fiscal year 2018: $24.86 million | Fiscal year 2017: $32.97 million | Fiscal year 2016: $25.24 million | Fiscal year 2015: $17.77 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: